Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SSRIs Will Add Fetal Risk Information To Labeling

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is seeking additional information about the possible risk of persistent pulmonary hypertension in newborns.

You may also be interested in...

SSRI Safety During Pregnancy Questioned Anew In Studies

FDA is seeking data on how often antidepressants are used by pregnant women to help gauge the significance of the findings.

Paxil CR "Dear Doctor" Letter Reflects New Labeling On Birth Defects

Preliminary results from a retrospective epidemiologic study suggest an increased risk of congenital malformations associated with the use of paroxetine by pregnant women over other antidepressants, the letter states.

Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial

The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts